High nuclear expression of proteasome activator complex subunit 1 predicts poor survival in soft tissue leiomyosarcomas [0.03%]
软组织平滑肌肉瘤中高核表达的蛋白酶体活化复合物亚基1预示不良生存率
Sha Lou,Arjen H G Cleven,Benjamin Balluff et al.
Sha Lou et al.
Background: Previous studies on high grade sarcomas using mass spectrometry imaging showed proteasome activator complex subunit 1 (PSME1) to be associated with poor survival in soft tissue sarcoma patients. PSME1 is invol...
Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone [0.03%]
地诺单抗治疗骨巨细胞瘤的现状与未解之题
Czar Louie Gaston,Robert J Grimer,Michael Parry et al.
Czar Louie Gaston et al.
Denosumab is a monoclonal antibody to RANK ligand approved for use in giant cell tumour (GCT) of bone. Due to its efficacy, Denosumab is recommended as the first option in inoperable or metastatic GCT. Denosumab has also been used pre-opera...
Solitary fibrous tumour presenting with a single bone metastasis: report of six cases and literature review [0.03%]
以单一骨转移为首发表现的孤立性纤维瘤六例并文献复习
Vittoria Colia,Salvatore Provenzano,Carlo Morosi et al.
Vittoria Colia et al.
Background: Solitary fibrous tumour (SFT) is a rare soft tissue sarcoma with a low metastatic potential. A higher metastatic rate is observed in the high-grade/dedifferentiated variant. The most common expected site of di...
Primary intraosseous meningioma: an osteosclerotic bone tumour mimicking malignancy [0.03%]
原发性骨内脑膜瘤：一种仿效恶性的骨硬化性肿瘤
M Vlychou,Y Inagaki,R Stacey et al.
M Vlychou et al.
Background: Sclerotic tumours of the calvarial bones are rare and may be due to primary and secondary bone tumours as well as extradural tumours of meningeal origin. ...
Dendritic and mast cell involvement in the inflammatory response to primary malignant bone tumours [0.03%]
恶性原发骨肿瘤炎症反应中树突细胞和肥大细胞的作用
Y Inagaki,E Hookway,K A Williams et al.
Y Inagaki et al.
Background: A chronic inflammatory cell infiltrate is commonly seen in response to primary malignant tumours of bone. This is known to contain tumour-associated macrophages (TAMs) and lymphocytes; dendritic cells (DCs) an...
Predictors of survival in patients with sarcoma admitted to the intensive care unit [0.03%]
重症监护病房收治的软组织肉瘤患者的预后因素分析
Rohan Gupta,Neda Heshami,Chouhan Jay et al.
Rohan Gupta et al.
Background: Advances in treatment of sarcoma patients has prolonged survival but has led to increased disease- or treatment-related complications resulting in greater number of admissions to the intensive care unit (ICU)....
Patterns of care for patients with advanced soft tissue sarcoma: experience from Australian sarcoma services [0.03%]
澳大利亚软组织肉瘤服务的晚期软组织肉瘤患者的治疗模式：经验分享
Susie Bae,Philip Crowe,Raghu Gowda et al.
Susie Bae et al.
Background: There is a paucity of data on the current management of patients with advanced soft tissue sarcoma (STS) in the Australian health care setting. This study utilised the Australian sarcoma database to evaluate t...
Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study [0.03%]
磷酸化胰岛素样生长因子I受体(p-IGF1R)和基质金属蛋白酶-3(MMP3)在晚期胃肠道间质瘤(GIST)中的表达：GEIS 19研究
Joan Maurel,Antonio López-Pousa,Silvia Calabuig et al.
Joan Maurel et al.
Background: Most GISTs have mutations in KIT or PDGFRA. Patients with advanced GIST with KIT exon 9, PDGFRA mutation or WT for KIT and PDGFRA have a worse progression-free survival (PFS) compared to patients with KIT exon...
The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report [0.03%]
ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS第三次欧洲骨肉瘤学术会议暨欧盟骨肿瘤精准医学联合研究网络研讨会纪要维也纳，奥地利，2015年9月24-25日
Leo Kager,Jeremy Whelan,Uta Dirksen et al.
Leo Kager et al.
This report summarizes the results of the 3rd Joint ENCCA-WP7, EuroSarc, EEC, PROVABES, and EURAMOS European Bone Sarcoma Network Meeting, which was held at the Children's Cancer Research Institute in Vienna, Austria on September 24-25, 201...
Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma [0.03%]
抗血管生成药物与肉瘤中细胞毒性化疗联合应用的临床前和临床研究
Kieuhoa T Vo,Katherine K Matthay,Steven G DuBois
Kieuhoa T Vo
Sarcomas are a heterogeneous group of mesenchymal malignancies. In recent years, studies have demonstrated that inhibition of angiogenic pathways or disruption of established vasculature can attenuate the growth of sarcomas. However, when u...